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Abstract
Mice expressing the tetracycline transactivator (tTA) transcription factor driven by the rat a-myosin heavy chain promoter
(a-MHC-tTA) are widely used to dissect the molecular mechanisms involved in cardiac development and disease. However,
these a-MHC-tTA mice exhibit a gain-of-function phenotype consisting of robust protection against ischemia/reperfusion
injury in both in vitro and in vivo models in the absence of associated cardiac hypertrophy or remodeling. Cardiac function,
as assessed by echocardiography, did not differ between a-MHC-tTA and control animals, and there were no noticeable
differences observed between the two groups in HW/TL ratio or LV end-diastolic and end-systolic dimensions. Protection
against ischemia/reperfusion injury was assessed using isolated perfused hearts where a-MHC-tTA mice had robust
protection against ischemia/reperfusion injury which was not blocked by pharmacological inhibition of PI3Ks with
LY294002. Furthermore, a-MHC-tTA mice subjected to coronary artery ligation exhibited significantly reduced infarct size
compared to control animals. Our findings reveal that a-MHC-tTA transgenic mice exhibit a gain-of-function phenotype
consisting of robust protection against ischemia/reperfusion injury similar to cardiac pre- and post-conditioning effects.
However, in contrast to classical pre- and post-conditioning, the a-MHC-tTA phenotype is not inhibited by the classic
preconditioning inhibitor LY294002 suggesting involvement of a non-PI3K-AKT signaling pathway in this phenotype. Thus,
further study of the a-MHC-tTA model may reveal novel molecular targets for therapeutic intervention during ischemic
injury.
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Introduction
The tetracycline-controlled transactivator (tTA) expression
system has been a widely used system for generating tissue-specific
and temporally-regulated expression of gene targets in mouse
models. The tTA-regulated system consists of two arms: one with
tissue specific expression of the tTA transactivator and the other
where the gene of interest is expressed under the control of a tTA
responsive promoter element [1]. The cardiac specific tetracycline-
regulated system consists of two transgenic lines: one expressing
the tTA transactivator under the control of the rat a-MHC
promoter and a second line possessing a target gene whose
expression is controlled by a tTA-responsive promoter [2]. A
double transgenic line created by crossing the two lines expresses
the target gene in a cardiac-specific manner in the absence of
tetracycline (Tet) or its analogue, doxycycline (Dox). In the
presence of tetracycline, tTA and tetracycline form a complex that
is unable to bind to the tTA responsive element leading to
inhibition of transgene expression. This system allows for analysis
of gene expression in adult animals without the confounding
effects due to transgene expression during development.
Expression of tTA under the control of the rat a-MHC
promoter (a-MHC-tTA) has allowed for the study of temporal and
spatial expression of various important molecules in cardiac tissue
[2,3]. The important roles of key elements such FrzA/sFRP-1,
PKC, nNOS and the glucocorticoid receptor in cardiac develop-
ment and disease processes have been elucidated using the tTA-
regulated expression system [2,4,5,6,7]. However, it has been
shown recently that expression of the tTA transcription factor
leads to a cardiomyopathy characterized by hypertrophy,
ventricular dilation and decreased ejection fraction in vivo; whereas
in vitro an increase in myofilament Ca
+ sensitivity and in
submaximal contraction were observed [8]. Furthermore, a
sustained protective effect was observed in the a-MHC-tTA mice
when subjected to ischemia/reperfusion (I/R) injury in vitro using
the isolated mouse heart preparation [9]. This sustained effect was
not abolished by inhibitors of mitochondrial ATP-sensitive K
+
channel, PKC, or adenosine receptors. Although the precondi-
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injury, it is tempered by the concurrent impairment in cardiac
function, and the presence of cardiac hypertrophy and ventricular
dilation in vivo.
We report here for the first time a sustained protective effect in
the a-MHC-tTA mice in the absence of hypertrophy, dilation, or
cardiac dysfunction in vivo. We observed that a-MHC-tTA hearts
had dramatically improved recovery of function compared to
control hearts following I/R injury. The observed protective effect
was not blocked by the pharmacological inhibitor LY294002
indicating that the protection was independent of the PI3K-AKT
signaling pathway. Furthermore, I/R injury induced in vivo by
coronary artery occlusion resulted in smaller infarcts in a-MHC-
tTA compared to control indicating that the a-MHC-tTA mice
are also protected from cell death in vivo. The present model offers
a promising finding in the field of cardiac I/R injury and for the
development of novel therapeutic agents especially with the
advancement of the technology of biologics in the pharmaceutical
industry. Dissecting the mechanisms involved in this protective
effect will greatly enhance our knowledge base of a very prevalent
condition in the Western population.
Materials and Methods
Animals and ethics statement
All methods involving animal use conform with the Guide for the
Care and Use of Laboratory Animals published by the National
Institutes of Health (NIH publication no. 85-23, revised 1996) and
were approved by the Animal Care and Use Committee of the
University of Illinois at Chicago. Mice expressing the tetracycline-
controlled transactivator (tTA) under the control of the rat a-
myosin heavy chain (aMHC-tTA) were purchased from Jackson
laboratories (stock number 003170). These mice, which were
initially maintained on an FVB/N background, were backcrossed
to C57BL/6 strain for multiple generations (at least 6). Transgenic
mice were identified by PCR screening. The tTA protein is
constitutively expressed in the myocardium and all mice were
maintained on a tetracycline-free drinking water. Control mice
were either non-transgenic C57BL/6 mice or mice possessing a
tet-regulated intersectin transgene [10]. These tet-transgenic mice
were maintained on a pure C57BL/6 background, do not express
intersectin in the absence of tTA, and appear indistinguishable
from pure-bred C57BL/6 mice. As with the tet-transgenic mice,
the a-MHC-tTA-transgenic mice do not show any overt
phenotype and appear indistinguishable from pure-bred C57BL/
6 mice.
Echocardiography
Transgenic male mice (5–9 months of age, 6 control and 5
aMHC-tTA-transgenic) were examined by echocardiography for
baseline measurements of cardiac function. Mice were initially
anesthetized with 3% isoflurane (Isoflurane, USP, Halocarbon
Products Corporation) in oxygen in an induction chamber and
maintained on isoflurane (1.0–1.5%) in oxygen using a nose cone
[11]. They were placed in the decubitus position on a warming
pad to maintain normothermia. The chest was shaved and hair
was removed with a depilatory cream (Nair). Warmed (37uC)
ultrasound gel (Aquasonic 100, Parker Laboratories, INC.,
Fairfield, N.J.) was applied to the chest. Transthoracic 2-D, M-
mode and pulsed Doppler images were acquired using a high-
resolution echocardiographic system (Vevo 770, Visual Sonics,
Toronto, ON, Canada) equipped with a 30-MHz mechanical
transducer. Left ventricular (LV) end-diastolic (LVIDd) and end-
systolic (LVIDs) diameters were obtained from the M-mode in
parasternal short axis view of LV at mid-papillary level, and
fractional shortening was calculated as FS%=(LVIDd-LVIDs)/
LVIDd6100%. All measurements were according to the leading-
edge method of the American Society of Echocardiography and
were based on the average of at least three cycles. LV end-diastolic
(EDV) and end-systolic (ESV) volumes were calculated from the
parasternal long axis and short axis views using the area-length
method as following: EDV=5/66Ad6Ld, where Ad, Ld are area
and length, respectively, of the LV in end-diastole; ESV=5/
66As6Ls, where As, Ls are area and length of the LV in end-
systole. Ejection fraction was calculated as EF%=(EDV-ESV)/
EDV.
Langendorff-perfused heart and ischemia/reperfusion
injury experimental protocol
For Langendorff-perfused heart experiments, 3 control and 4
aMHC-tTA mice age 3–5 months were used. Mice were injected
with 200 U (IP) of heparin 20 minutes prior to IP administration
of sodium pentobarbital (70 mg/kg). The heart was rapidly
excised and placed on ice-cold modified Krebs-Henseleit (KH)
buffer containing (in mM): 118.5 NaCl, 25 NaHCO3, 4.7 KCl, 1.2
MgSO4, 1.2 KH2PO4, 11 glucose, 2.5 CaCl2, 0.5 EDTA, 2 Na
Pyruvate; buffer was bubbled with 5% CO2/95% O2 at 37uC
(pH 7.4) [12,13,14]. Hearts were retrogradely perfused at a
constant pressure and ventricular pressure was monitored with a
fluid-filled balloon placed in the left ventricle (LV) and connected
to a 1.4Fr Millar pressure catheter (model SPR-671, Millar
Instruments, Houston, TX). Volume of the balloon was adjusted
to 10 mmHg and hearts were electrically paced via the right
atrium at a rate of approximately 450 beats/min. During each
experiment, the heart was allowed to stabilize for 20 minutes and
baseline values were collected at the end of stabilization period.
Hearts were then exposed to 30 min of global ischemia followed
by 60 min of reperfusion. During ischemia, temperature was
carefully kept at 37uC. Pacing was stopped 1 min prior to start of
ischemia and restarted 5 min after the start of reperfusion.
Developed pressure was recorded throughout the experimental
protocol.
Ischemia/reperfusion and infarct measurements
Male mice approximately 4–9 months were used for in vivo
ischemia/reperfusion experiments (5 control and 7 aMHC-tTA)
according to the American Physiological Society Guiding
Principles for the Care and Use of Animals in Research and
Training. Mice were initially anesthetized with isoflurane (4%)
followed by administration of etomidate (10 mg/kg BW; i.p.).
Subsequently, mice were intubated with an 18 gauge angiocath
sleeve and surgical anesthesia was maintained using 1.5%
isoflurane delivered through a vaporizer with 100% oxygen
(compressed gas). The vaporizer was connected in series to a
rodent ventilator (Harvard Instruments) with the stroke volume set
at 0.2 to 0.3 ml/min (based on body weight) and a respiration rate
of 135 per minute. A left thoracotomy was performed to expose
the heart and the pericardium was ruptured to access the left
anterior descending (LAD) coronary artery. The LAD was
occluded with 8-0 monofilament nylon suture approximately
5 mm from the ostium and the thoracotomy was temporarily
closed and covered with saline-soaked gauze while the animal
remained under anesthesia and ventilated. After 45 minutes of
occlusion, the suture was removed and the LAD coronary bed was
reperfused for an additional 120 minutes under anesthesia and
ventilation. At the conclusion of the reperfusion period, the mouse
was euthanized by overdose with isoflurane anesthesia and the
heart was explanted. To identify normal myocardium, the heart
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PBS and the LAD was re-occluded under a dissecting microscope
at the same site as performed for the in vivo experiments. Evans
Blue dye (1% in PBS) was then perfused retrograde through the
coronary vasculature and stained the entire heart except for the
LAD coronary bed. The hearts were then detached from the
cannula, placed in an acrylic heart matrix (Aster Industries,
McCandles, PA) and cooled at 220uC for an additional
30 minutes. To identify the area at risk (AAR) and infarcted area
(IA), the heart was cut from apex to base into seven, 1 mm thick
slices and each slice was incubated at 37uC for 25 min with 2%
2,3,5-triphenyltetrazolium chloride (Sigma Aldrich) dissolved in
PBS. Slices were fixed overnight in 10% buffered formalin for
analysis. To determine the AAR and IA, each slice was scanned
and digitized. AAR and IR were calculated for each of seven slices
per heart in the control and aMHC-tTA groups by planimetry as
previously reported [15,16] and expressed as a percentage of the
entire cross-sectional area (Evans Blue+AAR+IA) for each slice.
Creatine kinase release
Creatine kinase activity was determined in perfusion buffer
collected from the heart at baseline, at the onset of ischemia, and
at 15, 30, 45 and 60 min of reperfusion. Enzyme activity was
measured using a colorimetric assay using EnzyChrom Creatine
Kinase Assay Kit (ECPK-100; BioAssay Systems, CA).
Statistical analysis
All results are presented as mean 6 SEM. Statistical significance
was determined by a one-tailed Student’s t-test assuming unequal
variance. A p value,0.05 was considered significant.
Results
Echocardiography and in vivo cardiac function
a-MHC-tTA and control mice were analyzed by echocardiog-
raphy to determine LV wall thickness, fractional shortening and
ejection fraction. Table 1 shows that LV end-diastolic dimension
and end-diastolic posterior and septal wall thickness were not
changed in a-MHC-tTA compared to control. HR was similar in
both a-MHC-tTA and control. Furthermore, a slight increase in
fractional shortening and ejection fraction was observed in a-
MHC-tTA animals compared to control but these differences were
not statistically significant. There were no notable changes in
either LV mass or in HW/TL ratio between the two groups
indicating lack of hypertrophy in the a-MHC-tTA animals
compared to control. To further test whether hypertrophy
developed over time, two older a-MHC-tTA mice (12 and 14
months, respectively) were examined by echocardiography and
found to lack evidence of hypertrophy (data not shown). This 14
month old animal was initially examined at 7 months (included in
Table 1) and found to lack signs of hypertrophy. Thus, our results
indicate an absence of compensatory hypertrophy in the a-MHC-
tTA mice.
Ischemia-reperfusion injury in the isolated perfused heart
No-flow ischemia was performed for a total of 30 min in a-
MHC-tTA and control hearts followed by 60 min reperfusion.
Figure 1A shows LVDP at baseline, during ischemia, and from 5
to 60 min reperfusion. The control group showed a maximum
recovery of 35% whereas a-MHC-tTA had a robust recovery of
90% compared to baseline (Figure 1B). The time to return to 90%
of baseline LVDP was almost immediate (within the first 5 min of
reperfusion). Furthermore, LV systolic and diastolic functions
assessed by dP/dtmax and dP/dtmin, respectively, were significantly
higher in a-MHC-tTA compared to control after ischemia
(Figure 1C and D). When both groups were subjected to 40 min
ischemia, recovery in the a-MHC-tTA was at 55% of baseline
versus 12% in control (data not shown). These results demonstrate
a sustained preconditioning effect in a-MHC-tTA that is
comparable to ischemic preconditioning seen with brief periods
of ischemia followed by reperfusion.
PI3K inhibitor in ischemia-reperfusion injury
Administration of LY294002, a selective PI3K inhibitor, at
3 mM was sufficient to decrease the preconditioning effect induced
by two cycles of 5 min ischemia/5 min reperfusion prior to
30 min ischemia in control hearts (Figure 2). However, treatment
with 3 mM (data not shown) or 8 mM LY294002 did not abolish
preconditioning in the a-MHC-tTA hearts.
Creatine phosphokinase release as a measure of
cardiomyocyte damage
The release of creatine phosphokinase (CK) into perfusion
buffer is a marker for cardiomyocyte damage [17]. As shown in
Figure 3, control hearts exhibit significant elevated CK in
perfusion buffer within 15 min of reperfusion following ischemic
injury. In contrast, CK activity in perfusion buffer from a-MHC-
Table 1. Echocardiographic Measurements and Heart weight/tibia length.
tet MHC-tTA P value
N 65
LV end-diastolic dimension, mm 3.960.2 3.760.2 0.38
LV end-systolic dimension, mm 2.760.2 2.360.1 0.16
End-diastolic septal wall thickness, mm 1.060.06 1.060.05 0.26
End-diastolic posterior wall thickness, mm 0.960.03 0.960.05 0.38
Heart rate, beats/min 483633 510612 0.19
Fractional shortening, % 3263.0 3961.2 0.06
Ejection fraction, % 6364.0 7161.7 0.13
LV mass, mg 11469 11567 0.46
HW/TL (mg/mm) 7.960.4 (n=5) 8.360.3 (n=12) 0.23
Values are mean 6 SEM. P values are based on 1-tail Student’s t-test assuming unequal variance.
doi:10.1371/journal.pone.0030129.t001
MHC-tTA Confers Cardioprotection In Vivo
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30129tTA hearts was at or below baseline levels. The difference in
baseline CK levels is possibly due to cardiac muscle damage
during heart preparation for the experiment further highlighting
the increased resilience of the a-MHC-tTA hearts.
Coronary artery ligation
To assess whether the cardioprotection observed in the a-
MHC-tTA mice extended into an in vivo setting, we subjected
animals to a coronary artery ligation model. Control and a-MHC-
tTA animals were subjected to 45 min of left coronary artery
occlusion followed by 120 min of reperfusion. As shown in Fig. 4,
the size of infarct compared to the area-at-risk (AAR) was reduced
by 66% in the a-MHC-tTA animals compared to control mice.
Thus, the a-MHC-tTA mice exhibit significant protection from
cell death in vivo.
Discussion
The rat a-MHC-tTA mouse model is widely used to assess the
role of various gene products on cardiac function. However,
previous studies reported that this model exhibits significant
cardioprotection from I/R injury along with an associated cardiac
hypertrophy and mild cardiomyopathy [8,9]. In our attempts to
use this model to assess the function of the intersectin scaffold
protein in cardiac biology, we observed that the a-MHC-tTA mice
exhibited significant cardioprotection. In contrast to previous
studies [8,9], however, our mice lacked the reported cardiac
hypertrophy and cardiomyopathy phenotypes. Hemodynamic
measurements of control and a-MHC-tTA mice revealed no
Figure 1. a-MHC-tTA hearts were protected against I/R injury in vitro using the Langendorff-perfused heart. (A–B) LVDP was similar
between a-MHC-tTA and control hearts at baseline; however, after 30 min of ischemia, control hearts recovered to 35% of baseline LVDP values
whereas a-MHC-tTA had 90% recovery. (C–D) LV systolic and diastolic functions assessed by dP/dtmax and dP/dtmin respectively were significantly
higher in a-MHC-tTA compared to control after 30 min of ischemia. (N=3 for control and N=4 for aMHC-tTA, p,0.05).
doi:10.1371/journal.pone.0030129.g001
Figure 2. Effect of PI3K inhibition on the protection against I/R
injur in a-MHC-tTA hearts. Administration of LY294002 did not
abolish the protective effect seen in a-MHC-tTA hearts however it did
abolish protection imparted by IPC. (N=5 for a-MHC-tTA and N=3 for
a-MHC-tTA+8 mM LY294002, p,0.05).
doi:10.1371/journal.pone.0030129.g002
MHC-tTA Confers Cardioprotection In Vivo
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30129significant differences in the baseline cardiac properties of these
animals. Furthermore, heart weight to tibia ratios as well as
echocardiographic measurements indicated that the a-MHC-tTA
mice lacked an associated hypertrophy phenotype.
Another major finding of our study is that we demonstrate for
the first time that the a-MHC-tTA mice exhibit significant
cardioprotection from cell death in vivo. We observed a 66%
reduction in infarct size in a-MHC-tTA mice compared to control
Figure 3. Reduced cardiac muscle damage in a-MHC-tTA hearts subjected to I/R injury. Lack of cardiac muscle cell damage was apparent
in a-MHC-tTA compared to control where abundant creatine kinase levels were observed within 15 min of start of reperfusion. (N=4, p,0.05).
doi:10.1371/journal.pone.0030129.g003
Figure 4. Effect of in vivo I/R injury on a-MHC-tTA hearts. Significantly smaller infarct sizes were observed in a-MHC-tTA hearts subjected to
45 min of left coronary artery occlusion followed by 120 min of reperfusion. (A) Representative cross sections from control and a-MHC-tTA hearts. (B)
Average infarct size in control and a-MHC-tTA hearts. (N=5 for control and N=7 for a-MHC-tTA, p,0.05).
doi:10.1371/journal.pone.0030129.g004
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sion. Thus, a-MHC-tTA mice represent a potentially useful model
for discovery of novel factors involved in cardioprotection. Given
the differences in genetic background of our animals (C57Bl/6)
versus those of Baker and colleagues (FVB/N), it is possible that
there are genetic modifiers to this phenotype (i.e., hypertrophy and
cardiomyopathy) and that further characterization of the a-MHC-
tTA mice on different genetic backgrounds may lead to the
identification of such modifiers.
Cardioprotection for I/R injury can be induced by ischemic
preconditioning (IPC) which involves brief intermittent periods of
ischemia and reperfusion. There are two phases of IPC protection:
the acute phase which lasts 2 hrs and a delayed phase which
occurs 24 hrs post-ischemic injury [18]. The activation of PI3Ks is
thought to mediate the acute and the delayed phases of IPC by
phosphorylation of Akt, PKC (involved in acute phase) and PDK1
(involved in delayed phase). The cardioprotective phenotype of the
a-MHC-tTA hearts is qualitatively different from that induced by
IPC. In the latter paradigm, the heart gradually increases its
contractility upon start of reperfusion and reaches a maximum
plateau that is approximately 60% of baseline. In contrast, the a-
MHC-tTA hearts reach 70–80% function within 5 min of
reperfusion. In addition, the phenomenon of postconditioning is
thought to occur via Akt activation [19]. PI3K inhibitors
(wortmannin and LY294002) abolish the protection of both acute
and delayed IPC [18]. However, we report here for the first time
the lack of sensitivity of a-MHC-tTA cardioprotective phenotype
to PI3K inhibition. In addition, we did not observe changes in the
phosphorylation status of Akt in a-MHC-tTA hearts (data not
shown) further supporting the conclusion that the PI3K pathway is
not involved in a-MHC-tTA-stimulated cardioprotection. There is
a possibility that the PI3K/Akt pathway was activated early in
development in which case an increase in organ size should have
been observed during adulthood [20]. However, there were no
notable changes in heart size observed in the a-MHC-tTA.
Earlier investigations into the molecular pathways involved in a-
MHC-tTA phenotype revealed alterations in the expression of 153
genes [8]. Among these genes are myofilament proteins such as b-
tropomyosin and skeletal a-actin as well as genes involved in
intracellular transport, intracellular signaling in addition to kinase,
transferase and heat shock protein activities. Inhibition of tTA
function with doxycycline did not change the gene expression
profile. Furthermore, the cardiac tet-inducible system has been
recently reengineered using the attenuated mouse a-MHC
promoter to drive low level expression of tTA [21]. This modified
system induces robust expression of cardiac contractile and
signaling proteins in the absence of an overt phenotype such as
the one observed in this as well as other studies. One possible
explanation for these observed differences between the two MHC-
tTA promoters is that insertion of the rat a-MHC-tTA transgene
into the genome altered genetic elements (e.g., genes or micro
RNAs) that contribute to cardioprotection. Thus, identification of
the transgene insertion site may shed insight into the molecular
mechanisms involved in the observed gain-of-function phenotype
observed in the current study.
Although the tet-regulated system provides an attractive model
for chemical regulation of transgene expression, caution must be
used when utilizing the rat a-MHC-tTA transgenic model in the
study of cardioprotection due to the significant cardioprotective
response observed in the a-MHC-tTA alone. We strongly
encourage investigators to include these single transgenic animals
as controls for comparison to double transgenic animals. However,
our studies reveal that the cardioprotective phenotype associated
with the a-MHC-tTA transgene is not associated with any adverse
cardiac remodeling or dysfunction. Thus, identification of the
molecular mechanism underlying this cardioprotective phenotype
may uncover novel molecular targets for therapeutic intervention
during ischemic injury.
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